Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04758975
Title Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE)
Acronym VALUABLE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Paolo Ghia
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.